Efficacy and safety of Jentadueto® (linagliptin plus metformin)

Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations

(2013) Wendy L. Bennett et al.   ANNALS OF INTERNAL MEDICINE

Inappropriate metformin prescribing in elderly type 2 diabetes mellitus (T2DM) patients

(2012) M Kosmalski et al.   Advances in Medical Sciences

Dipeptidyl Peptidase-4 Inhibitors in the Elderly: More Benefits or Risks?

(2012) Giuseppe Paolisso et al.   ADVANCES IN THERAPY

Initial Combination with Linagliptin and Metformin in Newly Diagnosed Type 2 Diabetes and Severe Hyperglycemia

(2012) Thomas Haak   ADVANCES IN THERAPY

Linagliptin/Metformin Fixed-Dose Combination Treatment: A Dual Attack to Type 2 Diabetes Pathophysiology

(2012) Chrysi Koliaki et al.   ADVANCES IN THERAPY

Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: Dependence on glucose concentration and role of AMPK

(2012) James Sinnett-Smith et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

(2012) Odd Johansen et al.   Cardiovascular Diabetology

Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors

(2012) Larry K. Golightly et al.   CLINICAL PHARMACOKINETICS

Clinical Pharmacokinetics and Pharmacodynamics of Linagliptin

(2012) Ulrike Graefe-Mody et al.   CLINICAL PHARMACOKINETICS

Review of Linagliptin for the Treatment of Type 2 Diabetes Mellitus

(2012) Joshua J. Neumiller et al.   CLINICAL THERAPEUTICS

Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial

(2012) Stuart A. Ross et al.   CURRENT MEDICAL RESEARCH AND OPINION

Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: The HYPOCRAS study

(2012) A. Penfornis et al.   DIABETES & METABOLISM

Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study

(2012) J. B. McGill et al.   DIABETES CARE

Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study

(2012) T. Haak et al.   DIABETES OBESITY & METABOLISM

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

(2012) G. Schernthaner et al.   DIABETES OBESITY & METABOLISM

GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence

(2012) A. R. Meloni et al.   DIABETES OBESITY & METABOLISM

The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

(2012) D. Singh-Franco et al.   DIABETES OBESITY & METABOLISM

Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus

(2012) S. K. Thondam et al.   DIABETIC MEDICINE

Controversy about the relative efficacy of dipeptidyl peptidase IV inhibitors

(2012) A. J. Scheen   DIABETOLOGIA

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETOLOGIA

Linagliptin

(2012) Emma D. Deeks   DRUGS

Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment

(2012) André J Scheen   Expert Opinion on Drug Metabolism & Toxicology

Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus

(2012) Elisa Guarino et al.   EXPERT OPINION ON PHARMACOTHERAPY

Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes

(2012) Rosemarie Lajara   EXPERT OPINION ON PHARMACOTHERAPY

Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension

(2012) R. Gomis et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

What Next after Metformin? A Retrospective Evaluation of the Outcome of Second-Line, Glucose-Lowering Therapies in People with Type 2 Diabetes

(2012) Christopher Ll. Morgan et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Gliptin versus a sulphonylurea as add-on to metformin

(2012) André J Scheen et al.   LANCET

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

(2012) Baptist Gallwitz et al.   LANCET

Use of Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease

(2012) Nasser Mikhail   POSTGRADUATE MEDICINE

Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications

(2012) Aleksi Tornio et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Reappraisal of Metformin Efficacy in the Treatment of Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials

(2012) Rémy Boussageon et al.   PLOS MEDICINE

Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus

(2012) Thomas Rauch et al.   Diabetes Therapy

Treatment of elderly patients with type 2 diabetes mellitus: A systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors

(2011) Sherwyn L. Schwartz   American Journal Geriatric Pharmacotherapy

Clinical Pharmacokinetics of Metformin

(2011) Garry G. Graham et al.   CLINICAL PHARMACOKINETICS

Cellular and molecular mechanisms of metformin: an overview

(2011) Benoit Viollet et al.   CLINICAL SCIENCE

A Randomized, Open-Label, Crossover Study Evaluating the Effect of Food on the Relative Bioavailability of Linagliptin in Healthy Subjects

(2011) Ulrike Graefe-Mody et al.   CLINICAL THERAPEUTICS

Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review

(2011) Kathleen R. Richard et al.   CLINICAL THERAPEUTICS

A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes

(2011) Valerie Hutchins et al.   CURRENT MEDICAL RESEARCH AND OPINION

Inherited Variation in Vitamin D Genes Is Associated With Predisposition to Autoimmune Disease Type 1 Diabetes

(2011) J. D. Cooper et al.   DIABETES

DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials

(2011) A.J. Scheen   DIABETES & METABOLISM

Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency

(2011) K. J. Lipska et al.   DIABETES CARE

The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus

(2011) T. Forst et al.   DIABETES OBESITY & METABOLISM

Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin*

(2011) U. Graefe-Mody et al.   DIABETES OBESITY & METABOLISM

The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients

(2011) G. P. Fadini et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study1

(2011) D. R. Owens et al.   DIABETIC MEDICINE

Linagliptin

(2011) Lesley J. Scott   DRUGS

Sitagliptin/Metformin Fixed-Dose Combination

(2011) Claudine M. Chwieduk   DRUGS

Pharmacology of Dipeptidyl Peptidase-4 Inhibitors

(2011) Roberta Baetta et al.   DRUGS

Mechanisms Underlying Metformin-Induced Secretion of Glucagon-Like Peptide-1 from the Intestinal L Cell

(2011) Andrew J. Mulherin et al.   ENDOCRINOLOGY

Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation)

(2011) André J Scheen   Expert Opinion on Drug Metabolism & Toxicology

Metformin + saxagliptin for type 2 diabetes

(2011) André J Scheen   EXPERT OPINION ON PHARMACOTHERAPY

A review of gliptins in 2011

(2011) André J Scheen   EXPERT OPINION ON PHARMACOTHERAPY

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

(2011) Michael Elashoff et al.   GASTROENTEROLOGY

The Safety of Incretin-Based Therapies—Review of the Scientific Evidence

(2011) Daniel J. Drucker et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Metformin Use and Mortality Among Patients With Diabetes and AtherothrombosisMetformin Use With Diabetes and Atherothrombosis

(2010) Ronan Roussel   ARCHIVES OF INTERNAL MEDICINE

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

(2010) A. J. Scheen   DIABETES OBESITY & METABOLISM

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

(2010) M.-R. Taskinen et al.   DIABETES OBESITY & METABOLISM

Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials

(2010) C. Lamanna et al.   DIABETES OBESITY & METABOLISM

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial

(2010) S. Del Prato et al.   DIABETES OBESITY & METABOLISM

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes

(2010) T. Forst et al.   DIABETIC MEDICINE

Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin

(2010) André J Scheen   Expert Opinion on Drug Metabolism & Toxicology

Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes

(2010) Olivia J. Phung   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Addition of incretin therapy to metformin in type 2 diabetes

(2010) André J Scheen et al.   LANCET

Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects

(2009) E. U. Graefe-Mody et al.   CURRENT MEDICAL RESEARCH AND OPINION

Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 Diabetes: Interactions With Metformin

(2009) A. V. Matveyenko et al.   DIABETES

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

(2009) R. A. DeFronzo   DIABETES

Fixed-dose single tablet antidiabetic combinations

(2009) C. J. Bailey et al.   DIABETES OBESITY & METABOLISM

Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes

(2009) J. Cuthbertson et al.   DIABETIC MEDICINE

Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?

(2009) P. C. Butler et al.   DIABETOLOGIA

Assessing the Cardiovascular Safety of Diabetes Therapies

(2008) Allison B. Goldfine   NEW ENGLAND JOURNAL OF MEDICINE